Pre-clinical investigation of inhibition of the DNA damage response as a targetted therapy in myeloproliferative neoplasms shows synergism of ATR inhibitors with standard-of-care treatment.

Aleksander Ślusarczyk; Helen Bryant; Edwin Chen; Ian Hitchcock; Martin Zeidler; Andrew Chantry; Sally Thomas

doi:10.3390/IECC2021-09209

Previous Article in event

An Integrated Structure-based Approach for the Development of MDM2 inhibitors

Previous Article in session

Responsive signatures established by pharmaco-transcriptomic correlation analysis identifies subsets for PARP-targeted therapy and reveals potential synergistic interactors

Next Article in event

Elucidating the role of XRN2-mediated DNA repair programs

Next Article in session

USP9X inhibition enhances radiosensitisation of head and neck cancer cells in response to high-LET radiation by destabilizing centrosome proteins

Pre-clinical investigation of inhibition of the DNA damage response as a targetted therapy in myeloproliferative neoplasms shows synergism of ATR inhibitors with standard-of-care treatment.

Aleksander Ślusarczyk

^{*

1, 2},

¹,

³,

⁴,

⁵,

^{1, 6},

^{*

1, 7}

¹ Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK.
² Department of Immunology, Medical University of Warsaw, Warsaw, Poland
³ Department of Life Sciences, University of Westminster, London, UK
⁴ York Biomedical Research Institute, Department of Biology, University of York, York, UK.
⁵ The Bateon Centre, Department of Biomedical Science, Univesity of Sheffield, Sheffield, UK.
⁶ Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
⁷ Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Published: 29 January 2021 by MDPI in The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response session Poster

https://doi.org/10.3390/IECC2021-09209

Abstract:

Introduction

Myeloproliferative neoplasms (MPNs) are a group of haematological malignancies arising from haematopoietic stem cells with acquired driver mutations in JAK2, MPL and CALR. Increased replication stress is seen in the presence of JAK2V617F. Genes involved in the DNA double-strand break (DSB) repair pathways – BRCA-dependent homologous recombination repair (HRR) and DNA-dependent protein kinase-mediated non-homologous end-joining (D-NHEJ) are upregulated in MPN cells expressing mutated JAK2.

Aims

Using JAK2V617F and CALR (del 52) mutant cell lines:

Determine the effect of single-agent DNA damage repair (DDR) inhibitors on cell viability and apoptosis.
Evaluate the efficacy of DDR inhibitors in combination with hydroxyurea or ruxolitinib.

Materials and Methods

Cell lines expressing JAK2 (V617F)- HEL and CALR (del52)- MARIMO were treated with a drug panel comprising hydroxyurea, ruxolitinib, methotrexate, AZD6738 (ATRi), NU7441 (DNA-PKi), Olaparib (PARPi) and VE-821 (ATRi). AlamarBlue assay for cell proliferation and annexin V/ propidium iodide staining for flow cytometry were used to evaluate the toxicity.

Results

In JAK2 and CALR mutated cell lines, ATR inhibition by AZD6738 or VE-821, DNA-PKs inhibition by NU7441 and hydroxyurea each reduced viability, whereas PARP inhibition by olaparib had a minimal effect. The combination of ATR inhibition and hydroxyurea demonstrated high synergism in both apoptosis induction and proliferation arrest. Ruxolitinib alone had a modest effect in the presence of JAK2V617F and a minimal effect in CALR (del 52) mutated cells. Synergistic toxicity was observed for ruxolitinib and AZD6738/ VE-821 combination in JAK2 mutated cell line.

Conclusions

DDR inhibition reduces viability in cells expressing the driver mutations seen in MPNs. Most notably, ATR kinase inhibitors have a synergistic effect with the current standard-of-care treatment hydroxyurea. This study provides preliminary evidence that ATR inhibitors combined with standard therapies may be exploited in MPNs harbouring JAK2 and CALR mutations.

Keywords: myeloproliferative neoplasms, DNA damage repair inhibitors, ATR inhibitors, hydroxyurea, ruxolitinib

View paper View Poster

93 Reads
0 Recommendations